Section
This review details the phase 3 PANKU-Breast01 trial evaluating izalontamab brengitecan versus chemotherapy in pretreated HR+/HER2- breast cancer, highlighting significant PFS improvement and safety considerations in a Chinese cohort.
Analysis of 1,983 high-certainty DILI cases over two decades reveals shifting drug causes, declining severity, increased herbal and oncology-related cases, and higher mortality among elderly, patients with chronic liver disease, and oncolog
This review synthesizes evidence establishing Days at Home within 90 days (DAH-90) after gastrointestinal cancer surgery as a valid, meaningful patient-centered outcome, integrating survival, morbidity, and healthcare utilization to optimiz
A pivotal Phase 2 study demonstrates that derazantinib yields meaningful responses and progression-free survival in FGFR2-aberrant advanced intrahepatic cholangiocarcinoma, with an acceptable safety profile, supporting its role as a targete
This phase 3 trial shows that tarlatamab combined with durvalumab significantly improves overall and progression-free survival compared to durvalumab alone as maintenance therapy post-first-line chemoimmunotherapy in extensive-stage small-c
The PANKU-Lung01 phase 3 trial demonstrates izalontamab brengitecan significantly extends progression-free survival compared to platinum-based chemotherapy in EGFR-mutated advanced non-squamous NSCLC after failure of third-generation EGFR T
Surgical trauma from oral cancer reconstruction disrupts oral microbiota; staged oral irrigation, especially using bipolar water, supports microbial stabilization, lowers fungal presence, and improves patient comfort, aiding postoperative r
This review synthesizes phase 3 clinical evidence comparing divarasib, sotorasib, and adagrasib for KRAS G12C-mutated NSCLC, highlighting divarasib’s superior efficacy and safety, dose optimization insights, real-world data, and trans
This article reviews the incidence, timing, and risk factors of portomesenteric venous thrombosis (PVT) following pancreatic cancer surgery involving venous resection, highlighting the impact of surgical standardization and neoadjuvant radi
The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpressi
A large Swedish cohort study reveals that dental diseases and tooth loss are associated with increased risk of primary liver cancer, highlighting the importance of oral health in systemic disease prevention.
Sacituzumab tirumotecan combined with pembrolizumab significantly improves progression-free survival in PD-L1-negative advanced nonsquamous NSCLC compared to chemotherapy plus pembrolizumab, offering a promising new treatment standard with
The PRABITAS trial demonstrated that a 14-day trifluridine-tipiracil plus bevacizumab regimen is non-inferior to the conventional 28-day schedule in refractory metastatic colorectal cancer, with significantly reduced hematological and gastr
This international multicenter study shows no significant difference in surgical complications or survival between tangential and segmental portomesenteric venous resections during pancreatoduodenectomy for pancreatic cancer with limited ve
This article explores how acquired resistance to gemcitabine in pancreatic cancer leads to metabolic reprogramming that creates a vulnerability in the mevalonate pathway, offering a promising therapeutic target.
The I-SPY2.2 trial evaluated rilvegostomig combined with trastuzumab-deruxtecan in high-risk ERBB2-negative early breast cancer, showing promising pathologic complete response rates in immune-positive tumors while reducing exposure to anthr
Emerging evidence demonstrates that KRAS mutation analysis in secretin-stimulated duodenal lavage fluid offers a minimally invasive and sensitive approach for early detection of resectable pancreatic ductal adenocarcinoma, outperforming tra
Surgical randomized trials in gynecologic oncology revolutionize treatment approaches, but sustainability beyond publication requires structured implementation, credentialing, and vigilant post-trial surveillance to maintain safety, equity,
Temporary mesoportal and mesocaval portal vein bypasses are effective surgical strategies in pancreatectomy with portal vein resection, offering comparable perioperative outcomes and facilitating safe resection of advanced pancreatic tumors
This study evaluates adherence to NCCN guidelines and taper durations of corticosteroids in managing severe immune-related adverse events (irAEs) among gynecologic cancer patients receiving immune checkpoint inhibitors, revealing that guide
